Han Z - Search Results

1

Effectiveness and safety of camrelizumab in inoperable or advanced non-small cell lung cancer patients: a multicenter real-world retrospective observational study (CTONG2004-ADV).

Xu CR, Chen Q, Zhou C, Wu L, Li W, Zhang H, Li Y, Xu F, Xiong J, Wang Q, Zhang H, Jiang Y, Yin H, Wu Q, Dai Q, Hu J, Chen J, Zhang J, Wu G, Yin J, Zhao J, Liu B, Shan J, Sheng L, Chen Q, Han Z, Shi H, Liu Y, Chen J, Wu YL. Xu CR, et al. Among authors: han z. Transl Lung Cancer Res. 2023 Jan 31;12(1):127-140. doi: 10.21037/tlcr-22-852. Epub 2023 Jan 16. Transl Lung Cancer Res. 2023. PMID: 36762057 Free PMC article.

2

Efficacy and safety of second-line therapy with apatinib combined with chemotherapy as second-line therapy in advanced gastric cancer: a single-arm, open-label, prospective, multicenter study.

Zhang Y, Xu J, Wang Q, Ling G, Mao Y, Cai M, Yang Y, Mei J, Han Z, Feng J, Wu Y, Shi L, Wen S, Shen B. Zhang Y, et al. Among authors: han z. Ann Transl Med. 2022 Jun;10(11):641. doi: 10.21037/atm-22-2752. Ann Transl Med. 2022. PMID: 35813347 Free PMC article.

3

Real world experience with camrelizumab in patients with advanced non-small cell lung cancer: a prospective multicenter cohort study (NOAH-LC-101).

Wang R, Shi M, Ji M, Han Z, Chen L, Liu Y, Lu K, Liu L, Chen B, Zhang X, Miao L, Shu Y. Wang R, et al. Among authors: han z. Transl Lung Cancer Res. 2023 Apr 28;12(4):786-796. doi: 10.21037/tlcr-23-121. Epub 2023 Apr 25. Transl Lung Cancer Res. 2023. PMID: 37197631 Free PMC article.

4

Real-world treatment patterns and outcomes of pyrotinib-based therapy in patients with HER2-positive advanced breast cancer (PRETTY): A nationwide, prospective, observational study.

Li Y, Tong Z, Wu X, Ouyang Q, Cai L, Li W, Yu Z, Han Z, Wang X, Li M, Wang H, Li L, Yang J, Niu Z, Wang Q, Xu B. Li Y, et al. Among authors: han z. Int J Cancer. 2023 Nov 15;153(10):1809-1818. doi: 10.1002/ijc.34676. Epub 2023 Aug 6. Int J Cancer. 2023. PMID: 37543965

5

Pyrotinib in the Treatment of Women With HER2-Positive Advanced Breast Cancer: A Multicenter, Prospective, Real-World Study.

Zhang L, Wu X, Zhou J, Zhu M, Yu H, Zhang Y, Zhao Y, Han Z, Guo Y, Guan X, Wang X, Xu H, Sun L, Zhang J, Zhuang M, Xie L, Yu S, Chen P, Feng J. Zhang L, et al. Among authors: han z. Front Oncol. 2021 Jul 16;11:699323. doi: 10.3389/fonc.2021.699323. eCollection 2021. Front Oncol. 2021. PMID: 34336688 Free PMC article.

6

Comparison of effectiveness and safety of camrelizumab between HBV-related and non-B, non-C hepatocellular carcinoma: A retrospective study in China.

Liu H, Qin X, Xu Z, Wu M, Lu T, Zhou S, Yao N, Liu S, Shao Y, Han Z. Liu H, et al. Among authors: han z. Front Genet. 2022 Sep 9;13:1000448. doi: 10.3389/fgene.2022.1000448. eCollection 2022. Front Genet. 2022. PMID: 36160021 Free PMC article.

7

Therapeutic effectiveness of anlotinib combined with etoposide in extensive-stage small-cell lung cancer: a single-arm, phase II trial.

Wu Y, Zhou X, Zhao W, Wang Q, Han Z, Wang L, Zhou W, Zhou T, Song H, Chen Y, Yang K, Shi L, Pan B, Guo R, Zhou G, Jiang F, Feng J, Shen B. Wu Y, et al. Among authors: han z. Invest New Drugs. 2023 Dec;41(6):825-833. doi: 10.1007/s10637-023-01398-9. Epub 2023 Oct 14. Invest New Drugs. 2023. PMID: 37837490 Free PMC article. Clinical Trial.

8

Comparison of the Efficacy and Safety of PARP Inhibitors as a Monotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis.

Wang H, Wu M, Liu H, Zhou H, Zhao Y, Geng Y, Jiang B, Zhang K, Zhang B, Han Z, Du X. Wang H, et al. Among authors: han z. Front Oncol. 2021 Nov 24;11:785102. doi: 10.3389/fonc.2021.785102. eCollection 2021. Front Oncol. 2021. PMID: 34900739 Free PMC article.

9

Suppression of CCT3 inhibits melanoma cell proliferation by downregulating CDK1 expression.

Liu W, Zhang X, Chen C, Li Y, Yang C, Han Z, Jiang G, Liu Y. Liu W, et al. Among authors: han z. J Cancer. 2022 Mar 28;13(6):1958-1971. doi: 10.7150/jca.69497. eCollection 2022. J Cancer. 2022. PMID: 35399722 Free PMC article.

10

The prognostic value of the tertiary lymphoid structure in gastrointestinal cancers.

Yu A, Cao M, Zhang K, Yang Y, Ma L, Zhang X, Zhao Y, Ma X, Fan Z, Han Z, Wang H. Yu A, et al. Among authors: han z. Front Immunol. 2023 Oct 6;14:1256355. doi: 10.3389/fimmu.2023.1256355. eCollection 2023. Front Immunol. 2023. PMID: 37868990 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

9,342 results

Search Page